Homo Sildenafil is a new analog of Sildenafil (sc-338584). Sildenafil is a selective inhibitor of the type 5 cGMP phosphodiesterase (PDE5 inhibitor) which catalyzes the hydrolysis of 3',5'-cyclic guanosine monophosphate (cGMP). As a PDE5 inhibitor, Sildenafil has been reported to enhance neuro-, synapto- and angiogenesis in rat models of stroke and also is reported to be a mild vasodilator. Sildenafil has also been shown to prevent indomethacin-induced small intestinal ulceration formation through an NO/cGMP- dependent mechanism.
1. Koh, H.L. and Woo, S.O. 2000. Drug Saf. 23: 351-362. PMID: 11085343
2. Seftel, A.D. 2004. Clin Cardiol. 27: I14-I19. PMID: 15115191
3. Bednar, M.M. 2008. Curr Opin Investig Drugs. 9: 754-759. PMID: 18600581
4. Kato, N., et al. 2009. Dig. Dis. Sci. 54: 2346-2356. PMID: 19101800
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.